

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108

UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB Unknown
Gender: Unknown

Patient Identifiers: 01234567890ABCD, 012345

Visit Number (FIN): 01234567890ABCD **Collection Date:** 00/00/0000 00:00

Opioid Receptor, mu OPRM1, 1 Variant

ARUP test code 2008767

OPRM1, Specimen

Whole Blood

OPRM1 Genotype, Interpretation

GG

OPRM1 Phenotype, Interpretation

See Note

OPRM1, Interpretation

See Note

Indication for testing: predict opioid sensitivity.

Interpretation: Two copies of the OPRM1 G allele (rs1799971) were detected in this sample. Decreased sensitivity to opioid receptor agonists and increased sensitivity to opioid receptor antagonists are predicted. This patient may require higher or more frequent doses of opioid receptor agonists (e.g., morphine) to achieve adequate pain control. He/she may also be more likely to respond to opioid antagonists (e.g., naltrexone) in the treatment of alcohol and/or opioid dependency. This association of OPRM1 and drug sensitivity is not definitive and may be different for individual opioids.

Recommendation: Annotations for clinical application of this OPRM1 allele are available through the Pharmacogenomics Knowledge Base at: https://www.pharmgkb.org/gene/PA31945

This result has been reviewed and approved by

H=High, L=Low, *=Abnormal, C=Critical

4848



BACKGROUND INFORMATION: Opioid Receptor, Mu OPRM1, 1 Variant

CHARACTERISTICS: The mu opioid receptor is involved in mediating the clinical response to opioids (agonists and antagonists).
OPRM1 c.118A>G has been associated with lower sensitivity to opioid receptor agonists prescribed for pain control (e.g., morphine) and higher sensitivity to opioid receptor antagonists used in the treatment of alcohol and drug dependency (e.g., naltrexone). Risk of side effects to opioids is also associated with this genetic variant.

INHERITANCE: Autosomal codominant.

CAUSE: SNP rs1799971; OPRM1 c.118A>G (p.Asn40Asp), also known as G allele, alters response to opioids.
CLINICAL SENSITIVITY: Drug dependent.

METHODOLOGY: Polymerase Chain Reaction (PCR) and Fluorescence

Monitoring

ANALYTICAL SENSITIVITY and SPECIFICITY: Greater than 99 percent. ANALYTICAL SENSITIVITY and SPECIFICITY. Greater than 99 percent. LIMITATIONS: Only the targeted OPRM1 mutation, c.118A>G, will be detected. Diagnostic errors can occur due to rare sequence variations. Risk of therapeutic failure or adverse reactions with opioids may be affected by genetic and nongenetic factors that are not detected by this test. This result does not replace the need for therapeutic or clinical monitoring.

Please note the information contained in this report does not contain medication recommendations and should not be interpreted as recommending any specific medications. Any dosage adjustments or other changes to medications should be evaluated in consultation with a medical provider.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

EER Opioid Receptor, mu OPRM1

See Note

H=High, L=Low, *=Abnormal, C=Critical



VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
OPRM1, Specimen	23-324-117192	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
OPRM1 Genotype, Interpretation	23-324-117192	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
OPRM1 Phenotype, Interpretation	23-324-117192	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
OPRM1, Interpretation	23-324-117192	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
EER Opioid Receptor, mu OPRM1	23-324-117192	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical